Research at the Regional Center Vienna
Boehringer Ingelheim Regional Center Vienna (RCV) bears business responsibility for 33 countries in Central and Eastern Europe and Central Asia. RCV is one of the most important sites within the global group of companies and has its headquarters in Vienna (Austria), where about 3,200 people are employed. For over 20 years, Vienna has been a central pillar in Boehringer Ingelheim’s global oncology research network. We have a clear aspiration: to transform the lives of patients by delivering first-in-class therapies, with the ultimate goal of curing a range of cancers.
Scientific research in RCV
Our research approach is highly collaborative, with a primary focus on oncology. We have established a unique scientific ecosystem that brings our cancer research in Vienna together with biotech companies in Switzerland (T3 Pharma, AMAL Therapeutics and NBE Therapeutics and in Austria (ViraTherapeutics). Furthermore, we have a large network of collaborations and partnerships with universities, research institutes and biotech companies around the globe. This ecosystem allows the growth of our therapeutics portfolio and accelerates the development of novel cancer medicines.
Our generational commitment to driving scientific innovation is reflected by our clinical pipeline of cancer cell-directed and immune cell-directed therapies, as well as the smart combination of these approaches. The Vienna campus provides researchers with energy-efficient, and highly sustainable buildings and state-of-the-art technologies to get closer to our goal of curing cancer.
Fostering science and open innovation
We are committed to fostering basic research through our funding efforts to the Research Institute of Molecular Pathology (IMP) at the Vienna BioCenter, and our partnerships with a diverse array of research institutes, universities, and biotech companies across the globe. Our collaborative approach allows us to explore new frontiers in oncology, aimed at transforming the landscape of cancer treatment and provide efficient treatments to patients affected by this disease.
A cornerstone of our commitment to open science is our opnMe platform, through which we guarantee easy access to well-characterized pre-clinical tool compounds to scientists from around the world, and we search for new collaboration opportunities around key biologic questions.
"We're a team of motivated scientists with the common goal to bring new medicines to patients."
Dr. Paul Adam, Head of Research Site Vienna
Related Content
New cancer research building: Boosting innovation in oncology
“My ultimate goal is to cure cancer”
